LiPax
Non-Muscle Invasive Bladder Cancer (NMIBC)
Key Facts
About LIPAC Oncology
LIPAC Oncology is a private, clinical-stage biotech leveraging its proprietary neoliposomal drug delivery platform to enhance the therapeutic index of paclitaxel for localized cancers. Its lead candidate, LiPax, has completed a Phase 1-2a trial in NMIBC and is in preclinical development for several other intracavitary indications. The company's approach aims to maximize local efficacy and persistence while minimizing systemic toxicity, targeting significant market opportunities in areas like bladder cancer where current intravesical therapies are suboptimal.
View full company profileAbout LIPAC Oncology
LIPAC Oncology is a private, clinical-stage biotech leveraging its proprietary neoliposomal drug delivery platform to enhance the therapeutic index of paclitaxel for localized cancers. Its lead candidate, LiPax, has completed a Phase 1-2a trial in NMIBC and is in preclinical development for several other intracavitary indications. The company's approach aims to maximize local efficacy and persistence while minimizing systemic toxicity, targeting significant market opportunities in areas like bladder cancer where current intravesical therapies are suboptimal.
View full company profileAbout LIPAC Oncology
LIPAC Oncology is a private, clinical-stage biotech leveraging its proprietary neoliposomal drug delivery platform to enhance the therapeutic index of paclitaxel for localized cancers. Its lead candidate, LiPax, has completed a Phase 1-2a trial in NMIBC and is in preclinical development for several other intracavitary indications. The company's approach aims to maximize local efficacy and persistence while minimizing systemic toxicity, targeting significant market opportunities in areas like bladder cancer where current intravesical therapies are suboptimal.
View full company profileAbout LIPAC Oncology
LIPAC Oncology is a private, clinical-stage biotech leveraging its proprietary neoliposomal drug delivery platform to enhance the therapeutic index of paclitaxel for localized cancers. Its lead candidate, LiPax, has completed a Phase 1-2a trial in NMIBC and is in preclinical development for several other intracavitary indications. The company's approach aims to maximize local efficacy and persistence while minimizing systemic toxicity, targeting significant market opportunities in areas like bladder cancer where current intravesical therapies are suboptimal.
View full company profileTherapeutic Areas
Other Non-Muscle Invasive Bladder Cancer (NMIBC) Drugs
| Drug | Company | Phase |
|---|---|---|
| FL115 | Forlong Biotechnology | Phase 2 |
| Fosciclopirox (Ciclopirox Prodrug) | CicloMed | Pre-clinical/Phase 1 |
| Vesique® (APL-1202) | Asieris Pharmaceuticals | Phase 3 |
| DPX-formulated Products | BioVaxys | Phase 1 |
| Alpha1H | Hamlet Biopharma | Phase 2 |
| VAX014 | Vaxiion Therapeutics | Phase 1/2 |
| ZH9 | Prokarium | Phase 1 |
| Dabogratinib (Onc) | Tyra Biosciences | Phase 1/2 |
| NDV-01 | Relmada Therapeutics | Phase 2/3 |
| VDC Platform | Aura Biosciences | Preclinical |